| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sanjivani.co.in | |
| Market Cap | 34.89 Cr. | |
| Enterprise Value(EV) | 36.74 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 5.68 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 6.15 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 30.86 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | -5.02 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | -6.95 | Calculated using Price: 34.90 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.00 Cr. | 9,998,300 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company's products includes oral solids, small volume parenterals and sterile powder formulations. | ||
| 1 Day |
|
-3.06% |
| 1 Week |
|
-4.38% |
| 1 Month |
|
-10.63% |
| 3 Month |
|
-28.70% |
| 6 Month |
|
-28.92% |
| 1 Year |
|
-39.25% |
| 2 Year |
|
+232.38% |
| 5 Year |
|
+504.85% |
| 10 Year |
|
+66.99% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 4.66 | -7.19 | -58.98 | -596.93 | ||||||
| Return on Capital Employed (%) | 12.18 | 5.69 | -7.28 | -33.04 | -227.28 | -265.98 | 266.43 | |||
| Return on Assets (%) | 1.38 | -2.09 | -14.16 | -34.18 | -124.34 | -9.62 | -10.16 | 8.13 | 25.80 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 35 | 32 | 18 | -9 | -53 | -47 | -49 | -45 | -8 | -5 | |
| Non Curr. Liab. | 8 | 7 | 14 | 9 | 6 | 10 | 9 | 7 | 4 | 2 | |
| Curr. Liab. | 74 | 75 | 62 | 61 | 72 | 56 | 55 | 58 | 22 | 20 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 117 | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 17 | |
| Non Curr. Assets | 27 | 16 | 23 | 17 | 16 | 11 | 12 | 10 | 11 | 8 | |
| Curr. Assets | 90 | 98 | 70 | 43 | 9 | 7 | 4 | 9 | 8 | 9 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 117 | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | 17 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 159 | 133 | 115 | 33 | 18 | 25 | 16 | 25 | 31 | 31 | |
| Other Income | 3 | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 2 | 0 | |
| Total Income | 161 | 135 | 116 | 36 | 18 | 26 | 17 | 25 | 32 | 31 | |
| Total Expenditure | -149 | -128 | -121 | -56 | -70 | -27 | -17 | -23 | -26 | -24 | |
| PBIDT | 12 | 7 | -5 | -20 | -52 | -1 | 0 | 2 | 6 | 7 | |
| Interest | -8 | -8 | -9 | -5 | 0 | 0 | -1 | 0 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | 0 | ||||||||||
| PAT | 2 | -2 | -15 | -26 | -53 | -2 | -2 | 1 | 5 | 6 | |
| Adjusted EPS | 3 | -4 | -25 | -44 | -90 | -4 | -3 | 2 | 5 | 6 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 7 | 9 | -1 | 0 | 10 | 3 | 2 | 0 | 1 | 9 | |
| Cash Fr. Inv. | -1 | -1 | 9 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Cash Fr. Finan. | -6 | -8 | -7 | -1 | -10 | -3 | -2 | 0 | 0 | -8 | |
| Net Change | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Mon, 06 Feb 2023
Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Of The Company For The Quarter Ended December 31 2022 SANJIVANI PARANTERAL LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of Sanjivani Paranteral Limited will be held on Tuesday 14th February 2023 inter alia 1. To consider and approve the Un-Audited Financial Results of the Company for the quarter ended December 31 2022. 2. Any other matter with the permission of the chair. |
|
Wed, 11 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find enclosed herewith the Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 received from M/s Link Intime India Pvt Ltd. The Registrar and Transfer Agent of the Company for the quarter ended December 31 2022. |
|
Sat, 07 Jan 2023
Closure of Trading Window As per Securities And Exchange Board Of India (Prohibition Of Insider Trading) (Second Amendment) Regulations 2019 has mandated the closure of Trading window from the end of the quarter till the 48 hours from the declaration financial results.In view of the aforesaid it is hereby intimated that the trading window for dealing in Securities of the Company will remain closed for all Directors Officers Designated Persons of the Company and their immediate relatives with effect from Sunday January 01 2023 till 48 hours after the declaration of Un-Audited Financial Results of the Company for the quarter ended December 31 2022. |
| Wed, 08 Feb 2023 |
Close Crossing Last Month Close From Below
|
Close Within 52 Week Low Zone
|
High Decrease in 1 Month
|
High Decrease in 3 Months
|
High Decrease in 6 Months
|
Equities
M.F.
Sectors